Sun reports strong Q2 growth but says Indian pricing policy a concern
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has reported a 19% increase in net profits to Rs5.98 billion ($119.3 million) for the second quarter ended 30 September, aided in part by the exchange rate movement and growth in the domestic branded generics business. Net sales leapt by 42% to Rs18.95 billion.